Abstract: The present invention relates to bispecific antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: The present invention relates to novel tetravalent multispecific antibodies, their manufacture and use.

Abstract: The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.

Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Abstract: The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: The present invention relates to methods by which to produce sheet-like, wafer-like or film-like forms of drugs, confectionery, other food, cosmetics and the like for oral application or intake. The present invention is more particularly directed to the thermal treatment of carrier materials used in the production of such sheet-like, wafer-like or film-like forms. The thermal treatment removes contaminating or undesired substances from the carrier material.

Abstract: The present invention relates to multispecific antibodies based on antibodies that share a common light chain. The multispecific antibodies include modified heavy chains comprising by domain exchange a common light chain variable domain VL; and two modified light chains comprising by domain exchange variable heavy chain domains of a first antibody (VH1) and a second antibody (VH2), wherein one light chain is of kappa isotype and one light chain is of lambda isotype. The present invention also relates to methods for the manufacture of said antibodies and their use.

Abstract: A method for decorating substrates, in particular packaging, comprising the steps: printing at least one first decorative pattern (2) on the substrate using a first radiation-curable, preferably UV-curable, printing ink composition (3); printing at least one second decorative pattern (4), using a second radiation-curable, preferably UV-curable, printing ink composition (5), on at least part of the substrate (1) in a region near to the first pattern (2), chronologically before, after, or during the printing of the first pattern; radiation curing of the first and second printing ink compositions (3, 5), preferably directly after the printing of each pattern, the radiation-cured second printing ink composition having a lower glass transition temperature than the radiation-cured first printing ink composition; application of a decorative coating to the second pattern by means of a hot foil stamping process, a hot stamping foil comprising a decorative coating material being pressed against the printed substrate by

Abstract: The present invention relates to antibodies and Fc-region fusion polypeptides which are asymmetrically modified with respect to their Fc-receptor, especially their FcRn, and methods of using the same.

Abstract: Herein is reported the use of an antibody comprising an Fc-region with abolished FcRn binding for the transport of a soluble receptor ligand from the eye over the blood-ocular-barrier into the blood circulation.

Abstract: The invention provides anti-IGF-1R antibodies with abolished FcRn-binding and methods of using the same for the treatment of vascular eye diseases.

Abstract: An electrical contacting device for electrical physical contact with a specimen, particularly wafers, taking place in a contacting direction, with at least one conductor substrate which can be electrically connected to a testing device, at least one contact distance transformer and at least one contact head having electrical contact elements, particularly resilient contact elements, preferably serving to compensate different physical contact distances existing in the contacting direction particularly at the contact elements.

Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Abstract: Herein is reported an IgG class Fc-region comprising a first variant Fc-region polypeptide and a second variant Fc-region polypeptide, wherein the first variant Fc-region polypeptide is derived from a first parent IgG class Fc-region polypeptide and the second variant Fc-region polypeptide is derived from a second parent IgG class Fc-region polypeptide, whereby the first parent IgG class Fc-region polypeptide is identical to or different from the second parent IgG class Fc-region polypeptide, and the first variant Fc-region polypeptide differs from the second variant Fc-region polypeptide in one or more amino acid residues other than those amino acid residues in which the first parent IgG class Fc-region polypeptide differs from the second parent IgG class Fc-region polypeptide, and the IgG class Fc-region comprising the first variant Fc-region polypeptide and the second variant Fc-region polypeptide has an affinity to a human Fc-receptor that is different than that of an IgG class Fc-region comprising the fi

Abstract: The present invention relates to novel domain exchanged, bivalent, bispecific antibodies, their manufacture and use.

Abstract: The present invention relates to multispecific antibodies, their manufacture and use.

Abstract: The present invention relates to bispecific, bivalent antibodies against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: The present invention relates to bivalent, multispecific antibodies, especially bivalent, trispecific antibodies which bind to human HER1, human HER2, and human HER3, their manufacture and use.